Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study

This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.

开始日期2020-07-28

申办/合作机构

BioNTech SE

[+1]

ChiCTR2000034825 / Completed临床1期IIT

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study

开始日期2020-07-20

申办/合作机构

Jiangsu Provincial Center For Disease Control And Prevention

NCT04368728 / Completed临床2/3期

A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.
The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:
As a 2-dose (separated by 21 days) schedule;
At various different dose levels in Phase 1;
As a booster;
In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).
The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg.
Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity.
The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg.
To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days.
To reflect current and anticipated recommendations for COVID 19 vaccine boosters, participants in C4591001 who meet specified recommendations and have not already received one, will be offered a third dose of BNT162b2 after their second dose of BNT162.

开始日期2020-04-29

申办/合作机构

BioNTech SE

[+1]

100 项与 BNT-161b1 相关的临床结果

登录后查看更多信息

100 项与 BNT-161b1 相关的转化医学

登录后查看更多信息

100 项与 BNT-161b1 相关的专利（医药）

登录后查看更多信息

项与 BNT-161b1 相关的文献（医药）

2023-06-12·Scientific reports

COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs.

Article

作者: Rohleder, Nicolas ; Brunner-Weisser, Jonas ; Gündel, Harald ; Langgartner, Dominik ; Winkler, Raphael ; Jarczok, Marc N ; Weimer, Katja ; Reber, Stefan O

Ex vivo culturing of isolated PBMCs from individuals vaccinated with the coronavirus disease 2019 (COVID-19) vaccine BNT162b1 revealed a pronounced T cell response in the presence of the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The latter was 10-fold more pronounced than the ex vivo response of PBMCs from the same individuals to other common pathogen T cell epitope pools, suggesting COVID-19 vaccination to induce RBD-specific T cell responses and not to facilitate T cell (re)activity in general. In the current study we investigated whether COVID-19 vaccination long-lastingly affects plasma interleukin (IL)-6 concentrations, complete blood counts, ex vivo IL-6 and IL-10 secretion of PBMCs cultured under basal conditions or in the presence of concanavalin (Con) A and lipopolysaccharide (LPS), salivary cortisol and α-amylase, mean arterial pressure (MAP), heart rate (HR) as well as mental and physical health status. The study was initially designed to investigate whether the presence vs. absence of own pets during urban upbringing has protective effects against psychosocial stress-induced immune activation during adulthood. However, as COVID-19 vaccines were approved while the study was ongoing and as, therefore, both vaccinated and non-vaccinated individuals have been recruited, we were able to stratify our data set with respect to the COVID-19 vaccination status and to assess the long-lasting effects of COVID-19 vaccination on physiological immunological, cardiovascular and psychosomatic health parameters. This data is presented in the current study. We show that isolated PBMCs from individuals vaccinated against COVID-19 show a ~ 600-fold increase in basal and a ~ 6000-fold increase in ConA-induced proinflammatory IL-6 secretion, and a ~ 2-fold increase in basal and ConA-induced antiinflammatory IL-10 secretion, both in comparison with non-vaccinated individuals. In contrast, LPS-induced ex vivo IL-6 and IL-10 secretions were not affected by vaccination status, as were plasma IL-6 concentrations, complete blood counts, salivary cortisol and α-amylase, cardiovascular measures and psychosomatic health. In summary, our findings are of relevance for many clinical studies ran before/during the pandemic, clearly indicating that consideration of participants' vaccination status is critical, at least when assessing ex vivo PBMC functionality.

2023-01-01·Revista da Sociedade Brasileira de Medicina Tropical

Frequency And Factors Associated With Adverse Reactions After Administration of Inactivated COVID-19 Vaccine Among Health Workers.

Article

作者: Öztürk, Güzin Zeren ; Tektaş, Merve Hicret ; Basanmay, Muhammed ; Özdemir, Hacı Mustafa ; Taş, Beray Gelmez ; Akyol, Bestegül Çoruh ; Demir, İlknur

BACKGROUNDThe 2019 coronavirus (COVID-19) has precipitated a significant public health crisis. Our study aimed to evaluate the prevalence and risk factors associated with adverse reactions to the inactivated CoronaVac vaccine.METHODSThe study involved voluntary health workers who received CoronaVac vaccine. We documented the sociodemographic information of 2,019 participants who volunteered for our study. Of these, 1,964 and 1,702 participants were interviewed by phone 1 month after the first and second dose, respectively, during which they were queried about any adverse reactions.RESULTSWithin the first week after the first dose, adverse reactions were observed in 856 (43.3%) participants, with 133 (6.7%) experiencing them during the second week, and 96 (4.9%) people at the end of the first month. For the second dose, 276 individuals (16.2%) reported adverse reactions. The prevalence of both local and systemic adverse events ranged from 9.5-11.2% overall. Fatigue was the most common adverse reaction overall, while pain at the injection site was the most frequent local adverse reaction.CONCLUSIONSThe evaluation of both systemic and local side effects revealed no significant adverse reactions to the inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China). Our study found that the incidence of systemic and local adverse responses to the CoronaVac vaccination was lower than the rates reported in studies involving the recombinant adenovirus type-5, BNT162b1, and ChAdOx1nCoV-19 COVID-19 vaccines, all of which underwent the World Health Organization LULUC/PQ evaluation process.

2022-12-01·Journal of the European Academy of Dermatology and Venereology

A severe case of papulovesicular exthanthema with rhabdomyolysis after corona virus disease 2019 heterologous booster vaccination

Letter

作者: Tsubouchi, H. ; Maki, Y. ; Kanekura, T. ; Baba, A.

A review.This review is on severe case of papulovesicular exthanthema with rhabdomyolysis after corona virus disease 2019 heterologous booster vaccination.A 66-yr-old Japanese man was admitted for an emergency with skin rashes and muscle pain of his extremities.He was taking bezafibrate 200 mg/day for hyperlipidemia for 3 mo and received thethird dose booster mRNA-1273 vaccine (Moderna) 8 monthsafter the second vaccination with BNT162b1 (BioNTech-Pfizer).At the second vaccination, he experienced no severe adverse events (AEs) other than temporary fever.Various COVID-19 vaccine-related cutaneous reactions have been reported.In the present case, it is unclear that which is the cause of the severe symptoms, a single dose of mRNA-1273 or a robust immune response elicited by heterologous booster vaccination.

项与 BNT-161b1 相关的新闻（医药）

2022-11-08

·CPhI制药在线

疫苗 | 德国总理或推进复必泰上市？内地mRNA新冠疫苗获批为何困难重重？

关注并星标CPHI制药在线近日，德国总理朔尔茨（Olaf Scholz）展开就任以来首次访华行程，在中德两国总理联合记者会上，朔尔茨表示：在华生活的外国居民将可以打到由德国企业BioNTech研发的mRNA新冠疫苗Comirnaty。他还表示，这"只是第一步"，他期待未来获批接种该疫苗的群体可以继续扩大，直到全面免费接种。 Comirnaty是BioNTech研发的mRNA新冠疫苗BNT162b2，在中国由复星医药引进并负责商业化，其中文商品名为"复必泰"。受利好消息影响，BioNTech美股盘前一度大涨近7%。同时，内地mRNA新冠疫苗何时获批的话题再次引起人们的关注。复星医药：起个大早，赶了个晚集新冠疫情的爆发，使mRNA技术走上台前。mRNA即信使RNA，它通过将基因里的遗传信息传递到蛋白质合成工厂，进而指导蛋白质的合成。与传统技术相比，mRNA技术具有研发周期短、易于生产放大等优点。复星医药在新冠疫情爆发之初，就注意到了mRNA技术的潜力。2020年3月13日，复星医药和BioNTech签订合作协议，复星医药以31.63美元/股的价格认购BioNTech新增发行的158.08万股普通股，认购金额约为5000万美元，除此之外，复星医药还预先向BioNTech支付了8500万美元的技术许可费。以此获得BioNTech研发的mRNA新冠疫苗BNT162b1在大中华区的独家销售权。而辉瑞医药在两天后才拿下BioNTech另一款mRNA新冠疫苗BNT162b2在德国、土耳其之外的市场权益。此后，复星和辉瑞便分别在中国和美国开展了临床试验。由于2020年下半年国内新冠患者较少，复必泰临床进展缓慢。而美国当时正处于疫情爆发期，患者较多，辉瑞/ BioNTech的BNT162b2临床进展较快。因此，BNT162b2跑在了前面。 2020年底，BNT162b2成为首个在美获得紧急使用授权的mRNA新冠疫苗。2021年，BNT162b2已被165个国家/地区授权使用，其全球销售额为401亿美元。反观复星医药，mRNA新冠疫苗让其欢喜让其忧。2021年1月，复必泰（BNT162b1）在中国香港获紧急使用授权许可；同年2月，在中国澳门获特别许可进口批准；同年8月，复必泰在中国台湾地区获得紧急使用授权。截至2022年3月，复星医药已向港澳台地区供应了至少2500万剂复必泰疫苗。但是在中国大陆，BNT162b1却一直处于待审批状态。作为国内最早引进的mRNA疫苗，复必泰可谓是起了个大早，赶了个晚集。复必泰上市难的背后复必泰迟迟未能上市，原因主要有三点：一，中国大陆主要是出于安全性和有效性的慎重考虑。与FDA偏向鼓励药品创新不同，中国国家药监局尽可能地考虑安全。这是因为在不同人种间，疫苗的效果和副作用会有差异。而mRNA疫苗被FDA批准上市时，辉瑞的临床试验中，亚裔人数不够多，因此需要对疫苗的安全性慎重考量。二，中国大陆舆论对于进口mRNA新冠疫苗接受度不高，担心mRNA“篡改中国人基因”的声音不断。三，在新冠疫情之前，国家药监局对于mRNA疫苗的研究和应用了解有限。因此，监管层对此非常审慎，导致复必泰获批速度较慢。国内mRNA新冠疫苗布局情况根据公开资料统计，2020年初，国内曾有十多家药企进军mRNA新冠疫苗行业。然而今天只剩下大约4家还在坚持，除了复星医药外，还有艾博生物/沃森生物、斯微生物以及丽凡达生物。其中，斯微生物和丽凡达生物先后面临投资人撤资的窘境。目前只有艾博生物/沃森生物能与复星医药竞争。今年10月份，由艾博生物与沃森生物合作开发的mRNA新冠疫苗在印尼获得了紧急使用授权。目前，其III期临床研究正在多个国家/地区开展。曾经，莫德纳、辉瑞/BioNTech等企业的成功，将mRNA新冠疫苗赛道变成融资界的黄金赛道。但随着疫苗接种人群的普及，目前新冠疫情留给mRNA疫苗的时间不多了。复必泰作为中国最早引入的mRNA新冠疫苗，其审批进度及国产化受到舆论关注。此次德国总理对mRNA新冠疫苗的上市"推进"，似乎让复星医药看到了希望。参考来源： 1．《中国将允许国内外国人注射BioNTech新冠疫苗Comirnaty》医药魔方Info 2022-11-05； 2.《复必泰鲜为人知的故事》mRNA福星情报局 2022-03-27 ； 3. Chen GL, Li XF, Dai XH, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe.2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.PMID: 35098177; PMCID: PMC8786321. 智药研习社近期课程报名来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

疫苗信使RNA紧急使用授权合作

2022-07-06

·药融云

吸入式且可常温长时间保存的新款疫苗，已进入临床前测试

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。新冠肺炎（COVID-19）的全球大流行，就像拍了又拍的连续剧，总是续集不断。目前在全球范围内，至少有36款新冠疫苗在一个及以上的国家获得批准。这些疫苗大多通过肌肉注射接种，接种后产生在血液中循环的抗体。且在新冠疫苗的运输与储存方面，一些疫苗需要低温冷冻状态下才能运输和储存。为了更方便、快捷、有效地产生效果，科学家们一直在努力，希望能开发出可以有效刺激黏膜免疫，还能无创或无针接种，并且能在常温下长期稳定，就能弥补当前新冠疫苗的不足，也能提高疫苗接种率。7月4日，北卡罗莱纳州立大学程柯团队在Nature子刊Nature Biomedical Engineering发表了题为“Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine”的研究论文[1]。论述了该团队设计了一种基于外泌体（exosome）的、可吸入的新冠疫苗，并进行了临床前测试，该新冠疫苗可在冻干后在室温下稳定超过3个月。这无疑为今后的疫苗接种提供了更多选择。脂质体纳米颗粒（NP）已被广泛用于RNA疫苗的传递。例如，mRNA-1273（Moderna公司）、BNT162b1（BioNTech和辉瑞）和ARCoV mRNA疫苗（Walvax生物技术公司、苏州艾博基因生物科学有限公司和军事医学科学院）都是脂质纳米颗粒配制的RNA疫苗。该研究设计的新冠疫苗由与肺源性外泌体结合的重组新冠病毒受体结合域（RBD）组成，能够增强RBD在呼吸道和肺部的保留。SARS-CoV-2属于冠状病毒病毒家族，它们是包膜的正链RNA病毒，具有棘突蛋白复合物，可识别宿主细胞受体并与之结合。具体而言，SARS-CoV和SARS-CoV-2刺突蛋白S1亚基中的受体结合结构域（RBD）与宿主气道上皮血管紧张素转换酶2（ACE2）受体结合，然后通过S2亚基融合病毒和宿主膜，使RBD成为中和抗体和疫苗的特定靶标。以往的研究已经证明了SARS-CoV RBD作为强效中和抗体靶标的功效。SARS-CoV-2的体外研究表明，宿主抗体与RBD相互作用，与其结合并发挥中和作用。它还阻断了SARS-CoV-2和SARS-CoV进入表达ACE2的宿主细胞，这表明其作为病毒附着抑制剂的潜力。但仅管理RBD并不能实现特定的目标交付，也不能逃避降解或快速清除。RBD必须通过药物递送载体进行保护，该载体优化抗原呈递细胞（APC）的剂量。病毒样颗粒（VLP）和纳米颗粒（NPs）是强大的药物递送载体，外泌体是一种在体内发现的天然存在的细胞外囊泡，这使其成为靶向药物递送的天然和理想的递送囊泡，在靶向相同的组织受体细胞方面表现出色。它们含有由具有治疗特性的蛋白质，脂质和核酸组成的分子成分混合物。此外，外泌体可以通过创建表面修饰来表达蛋白质或肽来增强靶向性。研究团队从人类肺供体样本中衍生出肺球体细胞（LSC），其再生能力已经在啮齿动物模型中得到证明。该团队在之前已经研究了IPF啮齿动物模型中通过雾化处理LSC衍生外泌体（LSC-Exo）的安全性和生物分布，论文于2020年2月发表于《Nature Communications》[2]。LSC-Exo是用于肺部治疗的天然脂质体纳米颗粒（NP），来源于肺细胞的异质性群体，包括I型和II型肺细胞以及间充质细胞。同时，该团队通过利用LSC-Exo和RBD的特性，将RBD偶联到LSC-Exo（RBD-Exo）的表面上来设计可吸入的疫苗，从而创建了一种模拟病毒形态的病毒样颗粒（VLP），以此证实了啮齿动物肺支气管和实质的有效外泌体输送。与肌内注射COVID-19疫苗相比，吸入RBD-Exo诱导产生针对SARS-CoV-2的中和抗体，并触发黏膜免疫系统在肺部产生抗原特异性分泌IgA（SIgA）和T细胞反应，以抑制肺部上皮的病毒摄取（图1）。图1 吸入RBD-Exo VLP疫苗在小鼠中诱导SARS-CoV-2中和并保护其肺部该研究评估了RBD-Exo VLP疫苗在高剂量SARS-CoV-2感染小鼠中的保护作用，这些小鼠临床感染严重，且伴随着快速的体重减轻和严重的肺部病变。在接种两剂RBD-Exo疫苗后，小鼠肺部SARS-N蛋白水平和抗病毒蛋白1型干扰素反应基因MX1的表达均显著降低，且没有增加小鼠血清中IgE和RBD特异性IgE抗体的产生。表明两剂RBD-Exo吸入强烈诱导全身T细胞免疫反应，疫苗诱导的高效抗体将减少病毒复制，从而可以有效地保护小鼠免受SARS-CoV-2感染且没有过敏型反应。与肌内注射疫苗相比，吸入疫苗提供了两层额外的保护：疫苗引发的IgA和呼吸道黏膜中的常驻T细胞，为病毒通常进入和繁殖的部位提供有效的屏障；交叉反应性常驻T细胞，阻止病毒复制并减少病毒脱落和传播。更重要的是，与肌内注射相比，通过吸入途径进行黏膜疫苗接种有可能在呼吸道中赋予免疫力，阻止病毒传播。RBD-Exo雾化的另一个优点是非侵入性，这可能会鼓励那些害怕针头的人接种疫苗，从另一方面提高接种率。RBD-Exo冻干酸盐在−80°C，4°C和室温（21°C）下储存21 d（3周）或3个月。将RBD-Exo冻干产物分散在PBS中，并使用NTA检测其大小和浓度。此外，使用ELISA试剂盒对Exo上RBD的浓度进行定量。根据ICH指南，在（40±2）°C和75%±5%相对湿度下对RBD-Exo冻干剂进行了加速稳定性测试，结果表明，在3周，3个月，6个月样品稳定性良好。该研究也存在一些局限性。比如，外泌体的大规模生产和纯化具有挑战性，需要有一定基础的生产经验。外泌体的货物和表面配体可能会因批次不同有一定差异。由于NHS酯在水性条件下的不稳定性，DSPE-PEG-NHS与RBD的附着将与酯在反应缓冲液中的水解竞争。同时，吸入性疫苗通常不推荐用于有呼吸系统并发症的患者使用。综上所述，该研究开发的这种吸入式、室温稳定的病毒样颗粒（外泌体）疫苗，可作为有前景的新冠候选疫苗，值得未来的研究和开发，为将来的开发和研究提供了新思路和新选择。参考文献：[1]https://www.nature.com/articles/s41551-022-00902-5[2]https://www.nature.com/articles/s41467-020-14344-7—END—联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作数据库咨询 | 琳琳 18983288589（微信同号）会议合作 | 赖老师 13550291524（微信同号）园区合作 | 周老师 18725665133（微信同号）定制服务 | 陈老师 18908392210（微信同号）媒体合作 | 小薇 18908208341（微信同号）点击阅读原文，体验药融云专业服务！

疫苗信使RNA抗体合作免疫疗法

100 项与 BNT-161b1 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	土耳其	BioNTech SE	2020-04-29
新型冠状病毒感染	临床3期	美国	BioNTech SE	2020-04-29
新型冠状病毒感染	临床3期	阿根廷	BioNTech SE	2020-04-29
新型冠状病毒感染	临床3期	巴西	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	南非	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	阿根廷	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	美国	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	巴西	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	土耳其	BioNTech SE	2020-04-29
严重急性呼吸综合征	临床3期	德国	BioNTech SE	2020-04-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04523571 (CTgov)	临床1期	新型冠状病毒感染	144	Placebo (Placebo, 18-55 Years of Age)	淵襯鬱鹹鹹廠鬱網構夢(鹽衊顧積蓋構壓夢鬱糧) = 蓋壓壓顧積餘廠製醖鏇選獵積簾鹹鬱鬱醖構鏇 (遞獵壓鹹繭齋鬱選繭鹽, 蓋顧鑰鏇鏇膚窪蓋築獵 ~ 築艱網齋蓋構鏇鏇築選) 更多	-	2023-09-18
				Placebo (Placebo, 65-85 Years of Age)	淵襯鬱鹹鹹廠鬱網構夢(鹽衊顧積蓋構壓夢鬱糧) = 廠窪網鑰顧廠齋遞鹽窪選獵積簾鹹鬱鬱醖構鏇 (遞獵壓鹹繭齋鬱選繭鹽, 網獵醖顧網鏇糧淵願鑰 ~ 築獵觸積觸顧夢廠範醖) 更多
NCT04523571 (Pubmed \| Nat Med) 人工标引	临床1期	新型冠状病毒感染	144	BNT162b1	(鬱築鏇齋積簾夢糧築築) = Fever 願鬱廠鏇餘衊憲膚網鏇 (鹽鹽膚鬱積糧鏇鑰網夢 )	积极	2021-06-01
				Placebo
NCT04368728 (Pubmed) 人工标引	临床1期	新型冠状病毒感染	195	BNT162b1+BNT162b2	(蓋鑰繭繭襯繭衊襯顧淵) = BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1 蓋顧鏇鬱廠顧膚廠糧願 (願簾觸範壓簾襯簾膚糧 ) 更多	积极	2020-12-17
				Placebo